TransCode says Phase 1a trial shows 71.4% stable disease rate for TTX-MC138 in advanced solid tumors

• TransCode Therapeutics released updated follow-up results from its ongoing Phase 1a trial of TTX-MC138 in advanced solid tumors.
• Results have already been presented as an updated data cut, showing many patients achieved disease stabilization, with some remaining progression-free for a year.
• Safety profile remained acceptable across tested doses, supporting continued development without new tolerability signals.
• Exploratory biomarker work pointed to treatment-linked immune activation, reinforcing the clinical signal.
• Management is evaluating dose-expansion plans to confirm activity in selected cancers and molecularly defined patient groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280804PR_NEWS_USPR_____NE57281) on September 28, 2026, and is solely responsible for the information contained therein.